A Retrospective Study of Stage I to IIIa Lung Adenocarcinoma After Resection: What Is the Optimal Adjuvant Modality for Patients With an EGFR Mutation?-Reference-Cited by-同舟云学术

A Retrospective Study of Stage I to IIIa Lung Adenocarcinoma After Resection: What Is the Optimal Adjuvant Modality for Patients With an EGFR Mutation?

Published:2015-11 Issue:6 Volume:16 Page:e173-e181
ISSN:1525-7304
Container-title:Clinical Lung Cancer
language:en
Short-container-title:Clinical Lung Cancer

Author:

Lv Chao,An Chao,Feng Qin,Ma Yuanyuan,Li Shaolei,Wang Jia,Zhang Jianzhi,Wang Xing,Yan Shi,Fang Jian,Wang Yinxiang,Tan Fenlai,Yang Yue

Funder

PKU Hospitals

Publisher

Elsevier BV

Subject

Cancer Research,Pulmonary and Respiratory Medicine,Oncology

Reference33 articles.

1. The IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM Classification of malignant tumours;Goldstraw;J Thorac Oncol,2007

2. Surgical treatment of non–small-cell lung cancer;Lo Cicero,2009

3. Randomized study of adjuvant chemotherapy for completely resected stage I, II, or IIIA non–small-cell lung cancer;Scagliotti;J Natl Cancer Inst,2003

4. Cisplatin-based adjuvant chemotherapy in patients with completely resected non–small-cell lung cancer;Arriagada;N Engl J Med,2004

5. Vinorelbine plus cisplatin vs. observation in resected non–small-cell lung cancer;Winton;N Engl J Med,2005

Cited by 22 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A meta-analysis of adjuvant EGFR-TKIs for patients with EGFR mutation of resected non-small cell lung cancer;Medicine;2022-11-25

2. EGFR-Mutant Non-Small-Cell Lung Cancer at Surgical Stages: What Is the Place for Tyrosine Kinase Inhibitors?;Cancers;2022-04-30

3. Driver and novel genes correlated with metastasis of non-small cell lung cancer: A comprehensive analysis;Pathology - Research and Practice;2021-08

4. Targeted Next-Generation Sequencing Analysis Predicts the Recurrence in Resected Lung Adenocarcinoma Harboring EGFR Mutations;Cancers;2021-07-20

5. Efficacy of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in the Adjuvant Setting for Patients with Resected Epidermal Growth Factor Receptor Mutant Non-Small Cell Lung Cancer: A Meta-Analysis with 11 Trials;Oncology Research and Treatment;2021